NCT02947347 2026-03-17
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
Phase 3 Completed
Pharmacyclics LLC.
Eli Lilly and Company
Pharmacyclics LLC.
Eli Lilly and Company
Oncternal Therapeutics, Inc
Pharmacyclics LLC.